India Vaccines Market Size & Outlook, 2025-2033
India Vaccines Market Insights
- As highlighted in Reed Intelligence analysis, the India Vaccines Market, worth USD 2058.22 Million in 2024, is forecasted to achieve USD 3925.39 Million by 2033.
- The India market is anticipated to grow at a CAGR of 7.36% during the period 2025–2033.
- By 2024, Monovalent represented the largest share of the By Type market size.
- Monovalent is expected to remain the key growth driver within By Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, India accounted for 3.05% of the global Vaccines Market size.
- By 2033, United States is expected to lead the global Vaccines Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Vaccines Market size by 2033.
- India is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 3900.09 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 2058.22 Million |
| Market Size In 2033 | USD 3925.39 Million |
| Largest segment | Monovalent |
| Units | Revenue in USD Million |
| CAGR | 7.36% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Route of Administration |
|
| By Disease Indication |
|
| By Age Group |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
India Vaccines Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monovalent | XX.x | XX.x | XX.x | 1257.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Multivalent | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Vaccines Market By Route of Administration 2025-2033 (USD Million)
| By Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | XX.x | XX.x | XX.x | 948.63 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Parenteral | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nasal | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Vaccines Market By Disease Indication 2025-2033 (USD Million)
| By Disease Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viral | XX.x | XX.x | XX.x | 1187.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bacterial | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Vaccines Market By Age Group 2025-2033 (USD Million)
| By Age Group | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pediatric | XX.x | XX.x | XX.x | 1288.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Adult | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
